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STUDY QUESTION: Is the presence or absence of certain vaginal bacteria associated with failure or success to become pregnant after an in
vitro fertilization (IVF) or IVF with intracytoplasmic sperm injection (IVF-ICSI) treatment?
SUMMARY ANSWER: Microbiome profiling with the use of interspace profiling (IS-pro) technique enables stratification of the chance of
becoming pregnant prior to the start of an IVF or IVF-ICSI treatment.
WHAT IS KNOWN ALREADY: Live-birth rates for an IVF or IVF-ICSI treatment vary between 25 and 35% per cycle and it is difficult
to predict who will or will not get pregnant after embryo transfer (ET). Recently, it was suggested that the composition of the vaginal
microbiota prior to treatment might predict pregnancy outcome. Analysis of the vaginal microbiome prior to treatment might, therefore,
offer an opportunity to improve the success rate of IVF or IVF-ICSI.
STUDY DESIGN, SIZE, DURATION: In a prospective cohort study, 303 women (age, 20–42 years) undergoing IVF or IVF-ICSI treatment
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PARTICIPANTS/MATERIALS, SETTING, METHODS: Study subjects provided a vaginal sample before the start of the IVF or IVF-ICSI
procedure. The vaginal microbiota composition was determined using the IS-pro technique. IS-pro is a eubacterial technique based on the
detection and categorization of the length of the 16S–23S rRNA gene interspace region. Microbiome profiles were assigned to community
state types based on the dominant bacterial species. The predictive accuracy of the microbiome profiles for IVF and IVF-ICSI outcome of
fresh ET was evaluated by a combined prediction model based on a small number of bacterial species. From this cohort, a model was built to
predict outcome of fertility treatment. This model was externally validated in a cohort of 50 women who were undergoing IVF or IVF-ICSI
treatment between March 2018 and May 2018 in the Dutch division of the MVZ VivaNeo Kinderwunschzentrum Düsseldorf, Germany.
MAIN RESULTS AND THE ROLE OF CHANCE: In total, the vaginal microbiota of 192 women who underwent a fresh ET could be
analysed. Women with a low percentage of Lactobacillus in their vaginal sample were less likely to have a successful embryo implantation.
The prediction model identified a subgroup of women (17.7%, n = 34) who had a low chance to become pregnant following fresh ET. This
failure was correctly predicted in 32 out of 34 women based on the vaginal microbiota composition, resulting in a predictive accuracy of
94% (sensitivity, 26%; specificity, 97%). Additionally, the degree of dominance of Lactobacillus crispatus was an important factor in predicting
pregnancy. Women who had a favourable profile as well as <60% L. crispatus had a high chance of pregnancy: more than half of these
women (50 out of 95) became pregnant. In the external validation cohort, none of the women who had a negative prediction (low chance
of pregnancy) became pregnant.
LIMITATIONS, REASONS FOR CAUTION: Because our study uses a well-defined study population, the results will be limited to the
IVF or IVF-ICSI population. Whether these results can be extrapolated to the general population trying to achieve pregnancy without ART
cannot be determined from these data.
WIDER IMPLICATIONS OF THE FINDINGS: Our results indicate that vaginal microbiome profiling using the IS-pro technique enables
stratification of the chance of becoming pregnant prior to the start of an IVF or IVF-ICSI treatment. Knowledge of their vaginal microbiota
may enable couples to make a more balanced decision regarding timing and continuation of their IVF or IVF-ICSI treatment cycles.
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Introduction
In couples trying to conceive, 10–15% are affected by subfertility—
defined as 1 year of unprotected intercourse without achieving a
pregnancy (Evers, 2002). In such cases, subfertility is evaluated by
means of a medical workup of both partners, to determine whether
couples have an indication for ART. Common causes of subfertility
include ovulatory disorders, tubal disease and sperm abnormalities. In

























Not all subfertile couples trying to conceive will benefit from an
ART treatment. For example, couples with unexplained subfertility may
still have a good chance of conceiving spontaneously within the first
year after they have been diagnosed (Eijkemans et al., 2008; Steures
et al., 2006). To prevent under- and overtreatment, the decision as to
whether to wait or to start treatment requires careful consideration.
Various models have been developed for predicting the chances of a
spontaneous pregnancy. Hunault et al. (2004) developed a prediction
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year for couples with unexplained subfertility, which is integrated in
the daily practise of reproductive medicine in the Netherlands. The
prediction of Hunault is based on the following predictors: duration
of subfertility, the woman’s age, whether the infertility is primary or
secondary and the percentage of motile sperm. If the predicted chance
of spontaneous pregnancy in the following year is higher than their
chance with ART, couples are counselled to postpone ART treatment.
If the predicted chance is lower, ART improve the chances of pregnancy
(Brosens et al., 2004).
Commonly used ART procedures are IVF and IVF with intracy-
toplasmic sperm injection (IVF-ICSI). These procedures are invasive,
costly and do not guarantee a pregnancy. Only 25–35% of the women
become pregnant after the first embryo transfer (ET). If prior to
the start of treatment one could predict that the embryo implanta-
tion would likely be unsuccessful, then an invasive IVF or IVF-ICSI
treatment—with the accompanying physical, emotional and financial
burden—could be avoided or postponed.
Over the past decade, research has shown that beside the known
factors used in prediction models such as female age, sperm quality
and antral follicle count, outcome of assisted reproduction might also
be affected by the microorganisms of the urogenital tract (Bracewell-
Milnes et al., 2018; Egbase et al., 1996; Fanchin et al., 1998; Moore
et al., 2000; Pelzer et al., 2011; Selman et al., 2007). The collection
of microorganisms that live on or in the human body constitutes the
microbiota, and their complete genetic profile is generally referred to as
the microbiome. The microbiota can interact actively, both beneficially
as well as detrimentally, with the internal milieu of their host (Cho and
Blaser, 2012). The most common bacteria that inhabit the vagina belong
to the genus Lactobacillus (Ravel et al., 2011). Studies have shown that
the presence of certain Lactobacillus species during ART procedures
may have a positive impact on outcome (Eckert et al., 2003; Mangot-
Bertrand et al., 2013; Moore et al., 2000), whereas bacterial vaginosis
is associated with poorer results (Babu et al., 2017; Haahr et al., 2018).
The use of the composition of the vaginal microbiome as a predictor
for ART outcome has not yet been investigated. We aimed to answer
the following questions: first, is the presence or absence of certain
vaginal bacteria associated with failure or success to become pregnant
after an IVF or IVF-ICSI treatment? Second, can the composition of
the vaginal microbiome prior to treatment be used as an independent
predictor for IVF or IVF-ICSI outcome?
To answer these questions, we prospectively collected vaginal sam-
ples from subfertile women prior to their IVF or IVF-ICSI treatment,
recorded their IVF or IVF-ICSI outcome and analysed the vaginal
microbiome to determine its potential predictive value for IVF or IVF-
ICSI outcome after the first fresh ET. A predictive model was built on
this data of the prospective exploratory study and externally validated
in a clinic outside the Netherlands.
Materials and Methods
Two separate prospective studies were performed. First, a cohort of
subfertile women of reproductive age from eight IVF centres in the
Netherlands was used to build a prediction model for IVF and IVF-ICSI
outcome of fresh ET at Day 3. This study was named the ReceptIVFity
study (Koedooder et al., 2018). All included women intended to start




























































































































to be fulfilled were the following: women aged between 20 and 44
years and a male partner. Exclusion criteria were the following: women
with an indication for emergency IVF because of cancer or other
reasons, previous pregnancy or miscarriage in their medical history,
endometriosis American Fertility Score III/IV and pre-treatment with
a gonadotrophin-releasing hormone analogue or those who had used
hormonal contraceptives within 3 months prior to the start of their
IVF or IVF-ICSI intake. Women who had used the oral contraceptive
pill for the purpose of cycle timing prior to their treatment cycle were
eligible for this study.
Vaginal samples were obtained and analysed according to methods
previously described (Koedooder et al., 2018). Briefly, the interspace
profiling (IS-pro) technique was used to analyse the vaginal microbiota.
IS-pro is an open molecular technique, aimed at detecting and identify-
ing all bacteria in clinical samples. All resulting profiles therefore depict
the total community structure of the microbiota. Additionally, to put
our data in the context of other literature on the vaginal microbiota,
we also assigned the vaginal microbiome profile of each participant
to one of five community state types (CSTs), which are based on the
dominant microbial species as previously described by Ravel et al. After
exploration of the pregnancy outcomes per CST, the prediction model
was built with a small number of vaginal bacterial species identified by
IS-pro technique.
Finally, this model was externally validated in a second study cohort
in the Dutch division of the Medizinisches Versorgungszentrum (MVZ)
VivaNeo Kinderwunschzentrum Düsseldorf GmbH, Düsseldorf, Ger-
many. All women that presented for IVF or IVF-ICSI treatment, regard-
less of cycle number or diagnosis, were included sequentially in the
period from March 2018 to May 2018 as part of routine workup.
Approval for this study was obtained from the Institutional Medical
Ethical Review Board of the Erasmus University Medical Centre, and
participants provided written informed consent.
Results
Characteristics of the participants
In total, 303 women were included with the intention to provide a
vaginal swab for bacterial profile analysis. One woman did not provide
a vaginal swab, two women were excluded because they did not com-
plete the questionnaire and three samples of women were discarded
due to sampling error. Another 6 women were excluded because of
either the use of more than 3 weeks hormonal contraceptives prior
to the start of the IVF or IVF-ICSI treatment (n = 5) or miscarriage
in her medical history (n = 1), as specified in the exclusion criteria.
Retrospectively, 14 women collected the sample more than 2 months
prior to the ET, and these women were excluded from further analysis.
Hence, in total 26 women were excluded from further analysis due to
either protocol violations or selection errors.
Of the remaining 277 women, 85 women were withdrawn due to
the fact that there were no transferable fresh embryos after their first
IVF or IVF-ICSI attempt. The various reasons for this are summarized
in Table I of which abnormal response to hormone stimulation was
the majority (46/85). Thus, data of 192 women on the outcome
of IVF or IVF-ICSI after the fresh ET at Day 3 were available for
analysis. There were no differences in baseline characteristics between
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Table I Reasons for study participants to be withdrawn.
Stage of treatment Reason of drop out Total
......................................................................................................................................................
Hormone stimulation Too few follicles (n = 34) n = 46
Too many follicles (n = 10)
Stagnant growth (n = 2)
Puncture Risk of ovarian hyperstimulation syndrome (n = 8) n = 9
Escape intrauterine insemination (n = 1)
Laboratory No oocytes (n = 4) n = 19
No sperm cells (n = 3)
Insufficient cleavage (n = 1)
No embryo (n = 3)
Total fertilization failure (n = 8)
ET Embryo(s) primary frozen (n = 2) n = 2
Other Intercurrent disease (n = 6) n = 9
Relationship ended (n = 1)
Spontaneous pregnancy (n = 1)
No IVF or IVF-ICSI treatment (n = 1)
except ethnical subcategory Afro-Caribbean (Supplementary Table I).
For the final analysis, we compared the group of women that became
pregnant (n = 67) to those who did not (n = 125). Table II summarizes
the baseline characteristics of these two groups.
Univariate analysis
Univariate analyses showed that there were no statistical differences
between the two groups of pregnant women versus non-pregnant
women (Table II), including commonly used predictors for pregnancy
outcome (e.g. age, body mass index (BMI) and duration of infertility).
Women in the non-pregnant group had similar ages (mean ± SD age,
31.92 ± 4.17 years) compared to the women in the pregnant group
(age, 31.16 ± 3.67 years). The median BMI in the 2 groups was similar
(23.0 kg/m2). The duration of infertility was the same in both groups
(median (range) 2.43 (0.43–13.80) versus 2.21 (0.55–12.82) years;
P = 0.333). Finally, when comparing the remaining clinical character-
istics of the IVF and IVF-ICSI treatments, there were no significant
differences between the two groups (Supplementary Table II).
Analysis of the vaginal microbiome profile
The heatmap of the microbiological data from the IS-pro technique
of the vaginal samples shows clustering into five main groups (Fig. 1).
These groups could be identified as the five established CSTs.
Figure 2 shows the CSTs and the accompanying IVF or IVF-ICSI
outcome in each of them. CST IV and V were enriched for women
who did not become pregnant after the ET. CST IV contains 24 women,
of whom 17 (70.8%) did not become pregnant, whereas none of the
women (n = 3) in CST V became pregnant (100%). This proportion
was lower in the other CSTs (CST I, 68.3%; CST II, 62.5%; CST III,
55.4%).
The analyses for species content and microbial diversity per phylum
showed that the absence or presence of certain bacterial species was











































































low load of Lactobacillus, a high load of Proteobacteria or Lactobacillus
jensenii was correlated with failure to become pregnant. We found
that Gardnerella vaginalis strains were characterized by two distinct IS-
profiles. Only one of these IS-types was correlated with low pregnancy
rate, namely IS-pro type 1 (IST1). For certain bacterial groups, there
was no clear correlation between individual members of the groups;
however, there was a correlation between the diversity of these groups
and failure to achieve a pregnancy. These combined observations
resulted in a predictive algorithm for failure to become pregnant with
the following parameters: relative Lactobacillus load <20%, relative load
of L. jensenii >35%, presence of G. vaginalis IST1 or Proteobacteria
>28% of total bacterial load. This microbiome composition is referred
to as an ‘unfavourable microbiome profile’.
Unfavourable microbiome profile
Amongst the 192 women with a known IVF or IVF-ICSI outcome,
34 women had an unfavourable profile. Only 2 of these 34 women
(5.9%) became pregnant following a fresh ET. When this unfavourable
microbiome profile was used as a predictor for the failure to become
pregnant, the predictive accuracy in this group would be 94% (sensitiv-
ity, 26%; specificity, 97%). Univariate analyses showed that there were
no statistical differences within the general characteristics and the ART
procedure itself between women with a favourable and women with
an unfavourable microbiome profile (Tables III and IV).
Favourable microbiome profiles
In addition to profiling women with an unfavourable microbiome profile
(n = 34) with a low chance of pregnancy (5.9%), we could stratify
women in 2 more groups with either an average or relatively high
chance of pregnancy. This distinction could be made based on relative
abundance of Lactobacillus crispatus: we found that women with a high
relative abundance (≥60%) of L. crispatus (63/192 women, 33%) had a
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Table II Univariate analysis of baseline characteristics in women who became pregnant and women
who did not become pregnant.
Pregnant
......................................................................................................................................................
Yes (n = 67) No (n = 125) P-value f
Age 31.16 (3.67) 31.92 (4.17) 0.214c
≤30 year 22 (32.8%) 46 (36.8%) 0.584a
30–34 year 32 (47.8%) 49 (39.2%) 0.252a
35–39 year 13 (19.4%) 26 (20.8%) 0.819a
≥40 year 0 (0.0%) 4 (3.2%) 0.300b
Ethnicity
Caucasian 53 (79.1%) 113 (90.4%) 0.071a
Mediterranean 5 (7.5%) 3 (2.4%) 0.124b
Hindu 3 (4.5%) 2 (1.6%) 0.339b
Asian 2 (3.0%) 1 (0.8%) 0.268b
African 0 (0%) 3 (2.4%) 0.552b






Underweight (<20) 4 (6.0%) 10 (8.0%) 0.773b
Normal weight (20–24.9) 37 (55.2%) 68 (54.4%) 0.876a
Overweight (25–29.9) 21 (31.3%) 29 (23.2%) 0.276a
Obese class I (30–34.9) 3 (4.5%) 8 (6.4%) 0.749a
Obese class II (35–39.9) 0 (0%) 1 (0.8%) 1.000b
Obese class III (>40) 0 (0%) 1 (0.8%) 1.000b







Regular 53 (79.1%) 91 (72.8%) 0.331a
Mostly regular 6 (9.0%) 18 (14.4%) 0.275a
Irregular 6 (9.0%) 13 (10.4%) 0.747a
Absent 1 (1.5%) 1 (0.8%) 1.000b
Missinge 1 (1.5%) 2 (1.6%) -
Indication
Male factor 48 (71.6%) 80 (64.0%) 0.196a
Idiopathic 7 (10.4%) 22 (17.6%) 0.193a
Tube factor 2 (3.0%) 5 (4.0%) 1.000b
Cycle disorder 3 (4.5%) 4 (3.2%) 0.695b
Uterine factor 0 (0%) 1 (0.8%) 1.000b
Other 1 (1.5%) 3 (2.4%) 1.000b
Combinatione 4 (6.0%) 8 (6.4%) -
Missinge 2 (3.0%) 2 (1.6%) -
Use of medication
Yes 15 (22.4%) 25 (20.0%) 0.680a
No 51 (76.1%) 99 (79.2%)
Missinge 1 (1.5%) 1 (0.8%) -
Smoking
Yes 12 (17.9%) 18 (14.4%) 0.558a
No 53 (79.1%) 101 (80.8%)
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Yes (n = 67) No (n = 125) P-value f
Alcoholic consumption
Yes 37 (55.2%) 82 (65.6%) 0.122a
No 28 (41.8%) 38 (30.4%)
Missinge 2 (3.0%) 5 (4.0%) -
Urinary tract infection in prior 3 months
Yes 3 (4.5%) 4 (3.2%) 0.697b
No 64 (95.5%) 121 (96.8%)
Use of antibiotics in prior 3 months
Yes 7 (10.4%) 10 (8.0%) 0.569a
No 60 (89.6%) 115 (92.0%)
Duration of infertility 2.21 (0.55–12.82) 2.43 (0.43–13.80) 0.333d
Values are given as mean ± SD years, number (%) and median (range). BMI, body mass index (kg/m2).
aBy chi-square test.
bBy Fisher’s exact test.
cBy independent samples T-test.
dBy Mann–Whitney U test.
eThese subcategories are excluded from the analysis.
f Comparisons are made between analysed category and the other categories combined.
Figure 1 Heatmap of all clustered vaginal swab samples. Top section shows the clustering of all analysed microbiome profiles. The clusters
that coincide with the five known CSTs are shown (I–V). The columns represent the profile per individual. The rows represent the found species and the
length of the interspace region in units of nucleotides (nt). This can be clustered into three groups at phyla level: Bacteroidetes, FAFV and Proteobacteria.
Fig. 3B). In contrast, women with a high relative abundance (≥60%) of





ing pregnant following fresh ET (19/38 women; Fig. 3C). All women
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Age 31.75 (3.81) 31.19 (4.87) 0.461c
≤30 year 54 (34.2%) 14 (41.2%) 0.439a
30–34 year 67 (42.4%) 14 (41.2%) 0.895a
35–39 year 35 (22.2%) 4 (11.8%) 0.240b
≥40 year 2 (1.3%) 2 (5.9%) 0.145b
Ethnicity
Caucasian 136 (86.1%) 30 (88.2%) 0.806a
Mediterranean 8 (5.1%) 0 (0%) 0.354b
Hindu 4 (2.5%) 1 (2.9%) 1.000b
Asian 2 (1.3%) 1 (2.9%) 0.447b
African 2 (1.3%) 1 (2.9%) 0.447b






Underweight (<20) 13 (8.2%) 1 (2.9%) 0.470b
Normal weight (20–24.9) 86 (54.4%) 19 (55.9%) 0.832a
Overweight (25–29.9) 40 (25.3%) 10 (29.4%) 0.598a
Obese class I (30–34.9) 9 (5.7%) 2 (5.9%) 1.000b
Obese class II (35–39.9) 1 (0.6%) 0 (0%) 1.000b
Obese class III (>40) 1 (0.6%) 0 (0%) 1.000b







Regular 118 (74.7%) 26 (76.5%) 0.966a
Mostly regular 18 (11.4%) 6 (17.6%) 0.339a
Irregular 17 (10.8%) 2 (5.9%) 0.535b
Absent 2 (1.3%) 0 (0%) 1.000b
Missinge 3 (1.9%) 0 (0%) NA
Indication
Male factor 105 (66.5%) 23 (67.6%) 0.840a
Idiopathic 24 (15.2%) 5 (14.7%) 1.000b
Tube factor 5 (3.2%) 2 (5.9%) 0.608b
Cycle disorder 7 (4.4%) 0 (0%) 0.356b
Uterine factor 0 (0%) 1 (2.9%) 0.176b
Other 4 (2.6%) 0 (0%) 1.000b
Combinatione 9 (5.7%) 3 (8.8%) -
Missinge 4 (2.5%) 0 (0%) -
Use of medication
Yes 32 (20.3%) 8 (23.5%) 0.696a
No 124 (78.5%) 26 (76.5%)
Missinge 2 (1.3%) 0 (0%)
Smoking
Yes 24 (15.2%) 6 (17.6%) 0.680a
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Missinge 6 (3.8%) 2 (5.9%)
Alcoholic consumption
Yes 97 (61.4%) 22 (64.7%) 0.566a
No 56 (35.4%) 10 (29.4%)
Missinge 5 (3.2%) 2 (5.9%)
Urinary tract infection in prior 3 months
Yes 7 (4.4%) 0 (0%) 0.357b
No 151 (95.6%) 34 (100%)
Use of antibiotic treatment in prior 3 months
Yes 15 (9.5%) 2 (5.9%) 0.742b
No 143 (90.5%) 32 (94.1%)
Duration of infertility 2.34 (0.43–13.80) 2.37 (0.69–5.56) 0.954d
Values are given as mean ± SD years, number (%) and median (range), BMI= Body Mass Index (kg/m2). NA, not applicable.
aBy chi-square test.
bBy Fisher’s exact test.
cBy independent samples T-test.
dBy Mann–Whitney U test.
eThese subcategories are excluded from the analysis.
f Comparisons are made between analysed category and the other categories combined.
stratified into groups with a high and an average chance of pregnancy
based on relative abundance of L. crispatus alone. As described above,
in the group with L. crispatus abundance of ≥60%, 24% of women
became pregnant. In the group with L. crispatus abundance <60%, 53%
(50 of 95) of women became pregnant (Fig. 3D). The difference in
pregnancy rates between the high and average L. crispatus groups was
highly significant (P = 0.0003).
Multivariate analysis
We performed logistic regression analysis with failure to become
pregnant as the dependent variable and an unfavourable microbiome
profile, female BMI, female age and duration of infertility as covariates.
Twelve women with missing variables were excluded from the analysis.
The results of this analysis (n = 180) revealed that only an unfavourable
microbiome profile showed a statistically significant change in the risk
of failure to become pregnant (Table V).
External validation
We validated the predictive model as described above in an external
cohort of 50 women. Fourteen of these women had an unfavourable
microbiota profile, 13 had a high L. crispatus abundance profile and
23 had a low L. crispatus abundance profile. None of the 14 women
with an unfavourable profile became pregnant; 4 did not finish the IVF
procedure due to a lack of follicles, oocytes or suitable embryo(s) for
transfer. Of the 13 women with a high L. crispatus abundance profile, 4
(31%) became pregnant (3 ongoing pregnancies (75%)) and 4 did not
finish the IVF procedure. Finally, of the 23 women with a low L. crispatus
abundance profile, 12 (52%) became pregnant (11 ongoing pregnancies


































































In this prospective exploratory study, a subgroup of 34 women with
an unfavourable microbiome profile was identified in a subfertile pop-
ulation undergoing their first IVF or IVF-ICSI treatment with a 6%
pregnancy rate. In addition, we found that the abundance of L. crispatus
alone could further stratify the remaining 158 women with a favourable
microbiome profile into a subgroup of 95 women with high chance
(53%) of becoming pregnant and a group of 63 women with an average
chance (24%) of becoming pregnant. Our results indicate that micro-
biome profiling using the IS-pro technique enables accurate prediction
of both failure and success of fertility treatment. Women with an
unfavourable profile had a seven times lower chance of achieving a
pregnancy compared to the women who had a favourable vaginal
microbiome profile.
The overall pregnancy rate per cycle of the cohort was 35%, which
is similar to that reported by most clinics in the Netherlands in 2016
(average 34.2%) (Registratie, 2016). Women with a low L. crispatus
abundance had a one and a half times higher chance to become
pregnant after the first fresh ET, while women with a high L. crispatus
profile had a third times lower chance of becoming pregnant compared
to the overall pregnancy rate.
In defining the optimal parameters for stratifying patients into dif-
ferent pregnancy rate groups, it was found that different models can
be used to predict IVF and IVF-ICSI outcome. The prediction model
described here was built with a limited number of parameters, all
with well-established links to female health, in order to ensure high
generalizability. Relative abundance of various Lactobacillus species,
Proteobacteria and G. vaginalis are all widely described as important
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Figure 2 The CSTs and the accompanying pregnancy outcome.The composition of the vaginal microbiome per CST and the accompanying
distribution of pregnancy results (not pregnant or pregnant) per CST.
for the algorithm were chosen for best predictive accuracy with the
highest specificity. The model also proved to be effective in the external
validation cohort, underlining its generalizability.
A possible beneficial role of Lactobacillus species in ART has been
described in a number of recent studies. For example, the presence of
Lactobacilli has been associated with an increase in live-birth rate after
ART (Moore et al., 2000; Moreno et al., 2016). Moreno et al. (2016)
also found other positive correlations of a Lactobacillus-dominated
microbiome profile (>90% Lactobacillus spp.) with reproductive suc-
cess, namely higher implantation, pregnancy and ongoing pregnancy
rates.
A detrimental effect on ART outcome of non-Lactobacillus bacterial
species has also been described. Studies using culture-dependent tech-
niques found associations with poor reproductive outcomes, such as
decreased pregnancy rate (Fanchin et al., 1998; Selman et al., 2007),
implantation rate (Fanchin et al., 1998), conception rates (Eckert et al.,
2003; Salim et al., 2002; Selim et al., 2011), increased rates of early
pregnancy loss (Eckert et al., 2003) and reduction in live-birth rate









































ies using sequencing techniques, namely decreased pregnancy rates
(Haahr et al., 2016; Mangot-Bertrand et al., 2013) and lower implan-
tation, pregnancy and live-birth rates (Moreno et al., 2016).
The non-Lactobacillus bacterial species that have been found to be
associated with poor reproductive outcomes include Escherichia coli,
Staphylococcus, Streptococcus, Enterobacteriaceae, Atopobium vaginae,
and G. vaginalis species.
Strength of the ReceptIVFity study is that it is the first cohort
study in which the microbial composition was used as predictor
for IVF or IVF-ICSI outcome prior to the start of treatment. The
studies mentioned above have found associations between the
presence of microorganisms and reproductive outcomes during the
treatment.
We decided to study the vaginal microbiota instead of the uterine
microbiota for many reasons. Vaginal microbiota samples can be taken
non-invasively, and the bacterial load in the vagina is many orders of
magnitude larger than that in the uterus. Other considerations are
the fact that any microbes found in the uterus should generally be
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Table IV Univariate analysis of treatment characteristics of the IVF or IVF-ICSI procedure in women with a favourable
and unfavourable microbiome profile.
Microbiome profile
Favourable (n = 158) Unfavourable (n = 34) P-value f.....................................................................................................................................................................................
IVF or IVF-ICSI
IVF 53 (33.5%) 11 (32.4%) 0.875a
IVF-ICSI 104 (65.8%) 23 (67.6%)
Missinge 1 (0.6%) 0 (0%) -
Hormone downregulation
Decapeptyl 125 (79.1%) 26 (76.5%) 0.807a
Lucrin 20 (12.7%) 3 (8.8%) 0.771b
Orgalutran 6 (3.8%) 0 (0%) 0.593b
Cetrotide 4 (2.5%) 3 (8.8%) 0.105b
Synarel 0 (0%) 1 (2.9%) 0.176b
Missinge 3 (1.9%) 1 (2.9%) -
Hormone stimulation
Gonal-f 126 (79.7%) 28 (82.4%) 0.779a
Menopur 21 (13.3%) 5 (14.7%) 0.787b
Bemfola 9 (5.7%) 0 (0%) 0.366b
Pregnyl 0 (0%) 1 (2.9%) 0.178b
Puregon 1 (0.6%) 0 (0%) 1.000b
Missinge 1 (0.6%) 0 (0%) -
Endometrial thickness (mm) 10.37 (2.04) 9.97 (2.68) 0.344c
Follicle count 9.5 (2–23) 10 (2–20) 0.653d
Number of oocytes 9 (1–29) 9.5 (1–19) 0.864d
ET
SET 155 (98.1%) 34 (100%) 1.000b
DET 3 (1.9%) 0 (0%)
Values are given as mean ± SD, number (%) and median (range). IVF, in-vitro Fertilisation; IVF-ICSI, in-vitro Fertilisation with Intracytoplasmic Sperm Injection; mm, millimetre;
ET, embryo transfer; SET, single embryo transfer; DET, double embryo transfer.
aBy chi-square test.
bBy Fisher’s exact test.
cBy independent samples T-test.
dBy Mann–Whitney U test.
eThese subcategories are excluded from analysis.
f Comparisons are made between analysed category and the other categories combined.
impossible to distinguish contamination from true colonization in the
uterus.
A limitation of this study is that a well-defined study population was
used, limiting the results to the IVF or IVF-ICSI population. Whether
these results can be translated to the general population trying to
establish a pregnancy without ART cannot be determined from these
data.
Our findings show that a high abundance of Lactobacillus appears to
be advantageous for IVF and IVF-ICSI outcome, but a high abundance
(> 60%) of L. crispatus is not advantageous. Studies that generalize
on the possible beneficial effects of Lactobacilli on fertility will have
to take into account that different Lactobacillus species have different
characteristics, such as the ability to produce lactic acid from degrada-
tion of glycogen conversion. The acidity achieved by L. crispatus is the
highest compared to L. iners, L. jensenii and L. gasseri (Ravel et al., 2011).




































Table V Logistic regression analysis of associations with
a low chance of getting pregnant in IVF or IVF-ICSI
patients after fresh ET.
Variable OR 95% CI
.....................................................................................
Unfavourable profile 12.057 2.739–53.078
Age 1.024 0.937–1.119
BMI 1.071 0.982–1.167
Duration of infertility 1.072 0.895–1.285
OR, odds radio; 95% CI, 95% confidence interval; BMI, Body Mass Index.
facilitate the release of innate immune system components that inhibit
growth of bacteria other than Lactobacilli. At the same time, Lactobacilli
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Figure 3 The role of L. crispatus and L. iners in predicting pregnancy outcome.Relative rates of L. crispatus versus L. iners for each patient.
Each circle represents a patient, the colour of the dot shows pregnancy outcome (green, pregnant; red, not pregnant). A: Patients with an unfavourable
profile (34 of 192 women) are depicted as black crosses, they are removed from the data set in figures B–D. B: Of the remaining 158 women, 63 have
a relative abundance of L. crispatus ≥60%. The pregnancy rate in this group is 15/63 = 24%. C: Women with a relative abundance of L. iners ≥60%
show a pregnancy rate of 19/38 = 50%. D: When taking into account L. crispatus abundance alone, the group of women with a L. crispatus abundance
≤60% have a pregnancy rate of 50/95 = 53%.
cells, preventing the binding of other bacteria that might influence these
epithelial cells.
Witkin and Linhares (2017) also suggest that the ability to prevent
the influx of pathogenic microorganisms into the vagina without the
necessity of inducing pro-inflammatory immunity would appear to be
advantageous for a successful pregnancy outcome. A balance between
immunogenic resistance and tolerance is of importance to conceive
and establish a viable pregnancy, just as the implantation of the embryo
in the endometrium is dependent of the immune response in the female
reproductive tract (Robertson et al., 2011; van Mourik et al., 2009).
However, the extent of the interactions between the microbiome and
these immune responses is of yet unknown.
In the case of an unfavourable microbiome profile, women do not
generally suffer from a clinically evident infection. However, our results
show that women with an unfavourable test result have a limited
chance of success when transfer of a fresh embryo takes place within
2 months after the test was taken. Women with a low a prior chance to
become pregnant might prefer to avoid the unnecessary physical and
emotional burden of an IVF or IVF-ICSI treatment with a high change of












































due to an unfavourable profile will require follow-up research, which
is ongoing at the moment. Delaying a treatment when couples have
a strong desire to have children could lead to discontent when they
go through years of setbacks. However, the benefits may also be that
physical side effects, costs of treatment and emotional burden with
little chance of success could be saved.
Further research is needed to elucidate if women with an
unfavourable microbiome profile can actually switch to a favourable
profile and whether their chance of becoming pregnant subsequently
increases. Earlier research investigating the stability of the vaginal
microbiome revealed the dynamics of five major classes of bacterial
communities (CST I–V) and showed that some communities can
change markedly over short time periods, whereas the majority is
relatively stable over several months (Gajer et al., 2012). However,
there might also be women with fairly constant microbiota that do not
change over time.
One of the potential opportunities to improve results after IVF or
IVF-ICSI with the use of microbiome profiling is to counsel women
to postpone ART and await a favourable profile. The women could
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a switch from an unfavourable profile into a favourable one. Another
option is to postpone the first fresh ET, freeze the resulting embryos
and transfer them later in unstimulated cycles with a favourable micro-
biome profile. It is however yet unknown how often, when and why the
local microbiota composition changes spontaneously. There might also
be therapeutic options aiming at modulation of unfavourable vaginal
microbiota towards a more favourable profile, such as antibiotics, pre-
or probiotics (Tachedjian et al., 2018).
Future research will hopefully elucidate whether modulation of the
vaginal microbiota is possible and whether this may indeed improve
outcomes of IVF and IVF-ICSI in patients with an unfavourable profile.
However, the use of antibiotics might induce transient changes in
the microbiome and it is known that relapses to the initial state
frequently occur (Sobel and Sobel, 2015). More targeted options, such
as vaginal administration of probiotic Lactobacillus, aiming at specifically
improving the presence of Lactobacillus, may be more effective (Xie
et al., 2017).
Our suggestion is to reconsider starting the IVF or IVF-ICSI treat-
ment, or alternatively the ET, when a woman has an unfavourable
microbiome profile. Without a favourable microbiome, the implanta-
tion and subsequent embryo development seems to be compromised.
Future research should aim at unravelling the complex interactions
between the vaginal microbiome and the reproductive tract of their
host and thus enabling meaningful interventions to improve fertility
treatment outcome.
Supplementary data
Supplementary data are available at Human Reproduction online.
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